{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '1.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'The following abbreviations and specialist terms are used in this study protocol.', 'Table 1:', 'Abbreviations and Definitions of Terms', 'Abbreviation or Specialist Term', 'Explanation', '5-HT3', '5-hydroxytryptamine', 'ACS', 'American Cancer Society', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'ALT', 'alanine aminotransferase', 'AML', 'acute myeloid leukemia', 'AOA', 'American Optometric Association', 'API', 'active pharmaceutical ingredient', 'ASCT', 'autologous stem-cell transplantation', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the concentration versus time curve', 'AUC0-00', 'area under the concentration versus time curve from the time of', 'dosing extrapolated to infinity', 'BIW', 'twice weekly', 'bort', 'bortezomib', 'BP', 'blood pressure', 'BSA', 'body surface area', 'C', 'visit for in-clinic dosing only', 'CA', 'chromosomal abnormalities', 'CBC', 'complete blood count', 'CI', 'confidence interval', 'CIPN20', 'Chemotherapy-induced Peripheral Neuropathy', 'Cmax', 'maximum plasma concentration', 'CMH', 'Cochran-Mantel-Haenszel', 'CR', 'complete response', 'CRAB features', 'calcium elevation, renal failure, anemia, lytic bone lesions', 'CrCl', 'creatinine clearance', 'CRM1', 'chromosome region maintenance protein 1', 'CSR', 'clinical study report', 'Confidential', 'Page 12', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Abbreviation or Specialist Term', 'Explanation', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CXDX (eg, C1D1)', 'Cycle X Day X (eg, Cycle 1 Day 1)', 'D', 'day', 'Dex', 'dexamethasone', 'DOR', 'duration of response', 'DSMB', 'Data Safety Monitoring Board', 'eCRF', 'electronic case report form', 'ECG', 'electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'EoT', 'end of treatment', 'CCI', 'FACS', 'fluorescence activated cell sorting', 'FDA', 'Food and Drug Administration', 'FDG', 'fluorodeoxyglucose', 'FISH', 'fluorescence in situ hybridization', 'FLC', 'free light chain', 'G-CSF', 'granulocyte-colony stimulating factor', 'GCP', 'Good Clinical Practice', 'GM-CSF', 'granulocyte macrophage-colony stimulating factor', 'GR', 'glucocorticoid receptor', 'GSH', 'glutathione', 'hCG', 'human chorionic gonadotropin', 'HIV', 'human immunodeficiency virus', 'hr', 'hour', 'HR-QoL', 'health-related quality of life', 'IA', 'interim analysis', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'Ig', 'immunoglobulin', 'Confidential', 'Page 13', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Abbreviation or Specialist Term', 'Explanation', 'iFISH', 'interphase fluorescence in situ hybridization', 'IMWG', 'International Myeloma Working Group', 'IRB', 'Institutional Review Board', 'IRC', 'Independent Review Committee', 'ISS', 'International Staging System', 'ITT', 'intent-to-treat', 'IV', 'intravenous', 'Karyopharm', 'Karyopharm Therapeutics Inc.', 'KPT-330', 'selinexor', 'KM', 'Kaplan-Meier', 'LDH', 'lactate dehydrogenase', 'M', 'visit for MM disease assessments only', 'mAb', 'monoclonal antibody', 'MAP', 'maximum a posteriori', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'min', 'minutes', 'MM', 'multiple myeloma', 'MR', 'minimal response', 'MRD', 'minimal residual disease', 'MRI', 'magnetic resonance imaging', 'MTD', 'maximum tolerated dose', 'NCCN', 'National Comprehensive Cancer Network', 'NCI', 'National Cancer Institute', 'NGF', 'next generation flow', 'NGS', 'next generation sequencing', 'NHL', \"non-Hodgkin's lymphoma\", 'ORR', 'overall response rate', 'ORR1', 'overall response rate during SVdX treatment', 'OS', 'overall survival', 'PD', 'progressive disease', 'PDn', 'pharmacodynamics', 'PE', 'physical examination', 'Confidential', 'Page 14', 'Version 4.0']\n\n###\n\n", "completion": "END"}